Drugs / Dual CD33-CLL1 CAR-T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05016063 | Sep 2021 → Sep 2022 | acute myeloid leukemia | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual CD33-CLL1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05016063 ↗ |
| Known as | CD33-CLL1 CAR | “CD33-CLL1 CAR is a compound Chimeric Antigen Receptor immunotherapy with two distinct functional CAR molecules expressed on a T-cell, directed against the surface proteins CLL1...” NCT05016063 ↗ |
| Action | Deplete | “allows for a more comprehensive ablation of the disease” NCT05016063 ↗ |
| Modality | Cell therapy | “compound Chimeric Antigen Receptor immunotherapy with two distinct functional CAR molecules expressed on a T-cell” NCT05016063 ↗ |
| Target | CD33 | “directed against the surface proteins CLL1 and CD33” NCT05016063 ↗ |